Journal
JOURNAL OF HEART AND LUNG TRANSPLANTATION
Volume 31, Issue 3, Pages 325-331Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.healun.2011.09.010
Keywords
amyloidosis; heart transplantation; screening criteria; transthyretin; light chain
Ask authors/readers for more resources
Limited data exist regarding screening methods and outcomes for orthotopic heart transplantation own in cardiac amyloidosis. As a result, uncertainty exists over the best approach to OHT for cardiac amyloidosis and for the timing of critical post-transplant therapies. This article reviews 6 patients who underwent OHT for cardiac amyloidosis at the Stanford University Amyloid Center from 2008 to present. All patients with light-chain amyloidosis received chemotherapy in the interval between OHT and autologous hematopoietic stem cell transplant. Five patients remain alive up to 25 months after OHT, without evidence of recurrent cardiac amyloid deposition. A novel strategy of OHT, followed by light-chain suppressive chemotherapy before autologous hematopoietic stem cell transplant, is feasible for patients with light-chain amyloidosis. J Heart Lung Transplant 2012;31:325-31 (C) 2012 International Society for Heart and Lung Transplantation. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available